<?xml version="1.0" encoding="UTF-8"?>
<p id="para0004">Regarding coronaviruses, the potential therapeutic benefits of chloroquine were notably reported for SARS-CoV-1 
 <xref rid="bib0011" ref-type="bibr">[11</xref>,
 <xref rid="bib0042" ref-type="bibr">42]</xref>. Chloroquine was also reported to inhibit in vitro the replication of HCoV-229E in epithelial lung cell cultures 
 <xref rid="bib0043" ref-type="bibr">[43</xref>,
 <xref rid="bib0044" ref-type="bibr">44]</xref>. In 2009, it was reported that lethal infections of newborn mice with the HCoV-O43 coronavirus could be averted by administering chloroquine through the mother's milk. In vitro experiments also showed a strong antiviral effect of chloroquine on a recombinant HCoV-O43 coronavirus 
 <xref rid="bib0045" ref-type="bibr">[45]</xref>. Although chloroquine was reported to be active against Middle East respiratory syndrome coronavirus (MERS-CoV) in vitro 
 <xref rid="bib0046" ref-type="bibr">[46]</xref>, this observation remains controversial 
 <xref rid="bib0047" ref-type="bibr">[47]</xref>.
</p>
